We are a purpose-driven team, passionate about developing innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for underserved mental health disorders, beginning with postpartum depression (PPD), adjustment disorder (AjD) and generalized anxiety disorder (GAD). Leveraging our team’s extensive experience in neuroscience drug development, we are advancing RE104, a patented, clinical-stage drug candidate designed as a safe, fast-acting, short duration therapy for patients with underserved mental health disorders. RE104, the only 4-OH-DiPT prodrug in clinical development, achieved its primary endpoint and demonstrated clinically meaningful benefit in the RECONNECT Phase 2 clinical trial as a potential treatment for PPD. Based on these data, Reunion plans to advance RE104 into pivotal Phase 3 development in PPD in 2026. Additionally, Reunion is initiating the REKINDLE Phase 2 clinical trial evaluating RE104 as a potential treatment for AjD in cancer and other medical illnesses and expects to commence the RECLAIM Phase 2 clinical trial for the treatment of GAD in the first quarter of 2026.

ADVOCACY PARTNERS

Reunion Neuroscience is proud to partner with leading advocacy groups to build awareness of maternal mental health and drive increased support for pregnant and postpartum women.